Clinical trials
HIV-1-infection clinical trials
Below are recruiting hiv-1-infection clinical trials, each written for real people, not researchers. We’re tracking 89 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04375800RecruitingPhase 2
Doravirine for children with HIV infection and stable treatment
This Phase 2 study tests doravirine (a type of HIV medicine) in children with HIV who are about 4 weeks to under 12 years old and weigh under 45 kg. It aims to see whether this regimen can control the virus safely, and some children may continue into an extension if they benefit.
Aurora, ColoradoAges 4 weeks–11 years - NCT04653610Recruiting
Study immune signals in untreated HIV using extra samples
This study looks at tiny cell “messengers” in blood and stool to understand how HIV behaves before and after starting treatment. You may be eligible if you have untreated HIV (or you’re a healthy volunteer) and can commit to many sample visits, including long-term storage for 20 years.
Ghent, Oost-VlaanderenAges 18–65 - NCT06967753RecruitingPhase 4
Switching to a two-drug HIV regimen for transgender women
This trial tests if switching to a two-drug combination of dolutegravir and lamivudine is safe and effective for transgender women who already have undetectable HIV levels on a three-drug regimen. It aims to simplify treatment and reduce side effects.
Buenos Aires, Buenos Aires F.D.Ages 18 years+ - NCT02898987Recruiting
Study quality of care for adults living with HIV
This trial looks at how care is being provided to adults with HIV who may be on treatment or not, and regardless of immune strength. It may help improve future care plans by identifying what works best in real-world settings.
BelfortAges 18 years+ - NCT06612554Recruiting
Zinc supplements for HIV patients with low CD4 counts
This trial tests whether taking zinc supplements helps HIV patients who have low CD4 cell counts even when their virus is well-controlled. If your zinc levels are normal but your immune cells are slow to recover, this might be for you.
BarcelonaAges 18 years+ - NCT07473778Recruiting
Study of Lenacapavir for HIV Prevention
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
Birmingham, AlabamaAges 18 years+ - NCT02699736Enrolling by invitation
HIV and hepatitis C study in European adults
This study follows people living with HIV who also have hepatitis C antibodies, to better understand how HIV and hepatitis C affect health over time. You may be able to join if you meet the age and enrollment requirements, even if your hepatitis C virus level is currently undetectable.
Buenos AiresAges 16 years+ - NCT04949464Recruiting
Smoking quit coaching plus lung scans for people with HIV
This study tests a behavior-change program to help people with HIV quit smoking, along with routine low-dose lung CT scans to find warning signs early. It’s a feasibility study, meaning the main goal is to see if the approach is practical and acceptable, and if people can follow through.
La Jolla, CaliforniaAges 45–80 - NCT07650916RecruitingPhase 3
A study of two ultra-long-acting HIV shots
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
Phoenix, ArizonaAges 12 years+ - NCT05187429RecruitingPhase 1/Phase 2
Low-dose nivolumab for adults with HIV on stable therapy
This trial tests whether a low dose of nivolumab can safely affect the immune system in adults living with HIV who are already on stable HIV treatment. You may benefit by helping researchers understand a new approach, but the main goal is to check safety and early effectiveness.
Melbourne, VictoriaAges 18–65 - NCT06252402RecruitingEarly Phase 1
CAR T cells for HIV: A new immunotherapy study
This trial tests a new type of immune cell, called a CAR T cell, that is designed to target and kill cells infected with HIV. It may help control the virus without needing to take HIV medication all the time.
Duarte, CaliforniaAges 18 years+ - NCT07769983Enrolling by invitationPhase 1
HIV vaccine study for people on effective treatment
This study tests a new vaccine designed to help your immune system fight HIV better. It is for people with HIV who are already on effective antiretroviral therapy and have a well-controlled virus. The goal is to see if the vaccine is safe and boosts your body's natural defenses.
Bern, Canton of BernAges 18 years+ - NCT05077527RecruitingPhase 1
CAR-T treatment for HIV and aggressive B-cell lymphoma
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
Duarte, CaliforniaAges 18 years+ - NCT05674656RecruitingPhase 1/Phase 2
Testing dolutegravir and rilpivirine in HIV-positive children
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
Long Beach, CaliforniaAges 6–12 - NCT00187512Recruiting
Study of how HIV treatment changes outcomes over time
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
San Francisco, CaliforniaAges 18 years+ - NCT06799338Recruiting
Study of lenacapavir for HIV treatment in France
This study looks at how well lenacapavir works when added to a personalized HIV treatment plan. If you have HIV and received lenacapavir as your first dose between June 2023 and June 2024, this research may help understand its real-world effects.
Paris, Île-de-France RegionAges 18 years+ - NCT07415811Enrolling by invitation
Spironolactone for HIV-infected adults
This study tests the drug spironolactone, a medicine that helps your body balance fluids and potassium, in both HIV-positive and HIV-negative adults. The goal is to see how it affects a key protein complex in your cells. If you are HIV-positive, you need to have well-controlled HIV with undetectable virus levels and be on stable treatment.
São Paulo, São PauloAges 18–60
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv-1-infection?
- Yes. Clin2 currently lists 89 recruiting hiv-1-infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv-1-infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv-1-infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.